Abstract

Human monoclonal antibody (mAb) and their derivatives are one of the largest and fastest growing segments of biopharmaceutical industry. Recent application of recombinant DNA technology in antibody engineering space for generating and expressing antibodies has attained a significant amount of interest among scientists from industry and academia. Antibody engineering comprises introduction of the antibody combining sites (variable regions) into a host of architectures which further impact the therapeutic properties leading to further advantages and successes in patient treatment. In the ADC meeting I am going to discuss development of antibody libraries, mining strategies and how it can be utilized in the process of NBE development.